Видео ютуба по тегу Prof Petter Hillmen

prof peter hillmen Leeds part1
prof peter hillmen Leeds part1
Peter Hillmen
Peter Hillmen
Peter Hillmen
Peter Hillmen
ASM 2018 - Professor Peter Hillmen
ASM 2018 - Professor Peter Hillmen
prof peter hillmen Leeds part2
prof peter hillmen Leeds part2
An interview with Dr. Peter Hillmen - Understanding CLL
An interview with Dr. Peter Hillmen - Understanding CLL
Prof Peter Hillmen discusses exciting new data in CLL from EHA19
Prof Peter Hillmen discusses exciting new data in CLL from EHA19
Prof. Peter Hillmen: Polscy specjaliści mają ograniczone możliwości skutecznego leczenia białaczki
Prof. Peter Hillmen: Polscy specjaliści mają ograniczone możliwości skutecznego leczenia białaczki
Prof Peter Hillmen Global Expert explains CLL
Prof Peter Hillmen Global Expert explains CLL
ASH 2019 Interview - Prof Peter Hillmen - Challenges in the CLL/SLL treatment landscape
ASH 2019 Interview - Prof Peter Hillmen - Challenges in the CLL/SLL treatment landscape
ASH 2019 Interview - Prof Peter Hillmen - Treatment – patient choice
ASH 2019 Interview - Prof Peter Hillmen - Treatment – patient choice
Peter Hillmen, Opening remarks
Peter Hillmen, Opening remarks
Part 4 - Q & A - Prof. Peter Hillmen, UK
Part 4 - Q & A - Prof. Peter Hillmen, UK
Prof. Hillmen on whether CLL is curable today
Prof. Hillmen on whether CLL is curable today
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
ASH 2014: Prof John Gribben and Prof Peter Hillmen discuss recent advances in CLL (part 1)
Part 3 - Expert guidance on management of CLL patients with Acalabrutinib - Prof. Peter Hillmen, UK
Part 3 - Expert guidance on management of CLL patients with Acalabrutinib - Prof. Peter Hillmen, UK
iwCLL: what to expect
iwCLL: what to expect
ASH 2019 Interview - Prof Peter Hillmen - CLL updates from ASH 2019
ASH 2019 Interview - Prof Peter Hillmen - CLL updates from ASH 2019
COVID-19 and Blood Cancer an Expert's View - with Prof Peter Hillmen
COVID-19 and Blood Cancer an Expert's View - with Prof Peter Hillmen
Treatment options for patients with CLL who progress after BTK inhibitor therapy
Treatment options for patients with CLL who progress after BTK inhibitor therapy